Pathobiology of Neurologic Diseases¶
Chapter 435 | Part 13: Neurologic Disorders
KEY CLINICAL POINTS¶
- Microglia and astrocytes play central roles in neuroinflammation, synaptic pruning, and neurodegeneration through complex interactions with neurons and other glial cells.
- Prion diseases (e.g., Alzheimer's, Parkinson's) involve misfolded proteins (A β , α -synuclein, tau) that aggregate and trigger neurotoxicity via oligomer formation and impaired autophagy.
- Stem cell-derived organoids and iPSC models are revolutionizing the study of neurodegenerative diseases by enabling patient-specific disease modeling and drug screening.
- Neuroimmune interactions, including the role of the microbiome and gut-brain axis, are emerging as key factors in the pathogenesis of neurologic disorders.
- Targeting complement pathways, microglial activation, and protein clearance mechanisms represents promising therapeutic strategies for neurodegeneration.
1. DEFINITION & OVERVIEW¶
The pathobiology of neurologic diseases encompasses the molecular, cellular, and systemic mechanisms underlying neurodegeneration, neuroinflammation, and neuroimmune disorders. This chapter explores the roles of glial cells (microglia, astrocytes, oligodendrocytes), prion proteins, and stem cell biology in neurologic pathogenesis.
Table 435-1: Prion-Based Classification of Neurodegenerative Diseases¶
| NEURODEGENERATIVE DISEASE | CAUSATIVE PRION PROTEINS |
|---|---|
| Creutzfeldt-Jakob disease (CJD) | PrPSc |
| Kuru | PrPSc |
| Gerstmann-Sträussler-Scheinker disease (GSS) | PrPSc |
| Fatal insomnia | PrPSc |
| Bovine spongiform encephalopathy (BSE) | PrPSc |
| Scrapie | Pr,Sc |
| Chronic wasting disease (CWD) | PrPSc |
| Feline spongiform encephalopathy | PrPSc |
| Transmissible mink encephalopathy | PrPSc |
| Alzheimer’s disease (AD) | Ab fi tau |
| Down syndrome | Ab fi tau |
| ALS-parkinsonism dementia complex (PDC) of Guam | Ab fi tau |
| NEURODEGENERATIVE DISEASE | CAUSATIVE PRION PROTEINS |
|---|---|
| Parkinson’s disease (PD) | a-Synuclein |
| Dementia with Lewy bodies | a-Synuclein |
| Multiple-system atrophy | a-Synuclein |
| Frontotemporal dementias (FTDs) | Tau, TDP43, FUS |
| Chronic traumatic encephalopathy (CTE) | Tau |
| Amyotrophic lateral sclerosis (ALS) | SOD1, TDP43, FUS |
| Huntington’s disease (HD) | Huntingtin |
1.1 Neuroimmunology and Neuroinflammation¶
Neuroimmunology integrates immune responses with CNS function. Microglia and astrocytes mediate neuroinflammation, while oligodendrocytes support myelin integrity. Dysregulated immune responses contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
1.2 Prion Diseases and Protein Aggregation¶
Prion diseases (e.g., Creutzfeldt-Jakob disease) involve misfolded prion proteins (PrPSc) that propagate neurodegeneration. Similar mechanisms underlie amyloid-beta (A β ) and tauopathies, with oligomer formation and impaired autophagy as key pathogenic features.
2. EPIDEMIOLOGY¶
Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) predominantly affect older adults, with incidence increasing with age. Genetic factors (e.g., APOE ε 4 for AD) and environmental exposures (e.g., head trauma for CTE) contribute to risk. Neuroinflammatory conditions like multiple sclerosis show geographic and demographic variability.
2.1 Risk Factors¶
Age, family history, genetic mutations (e.g., APP, PSEN1/2 for AD), and environmental toxins (e.g., pesticides for Parkinson's) are major risk factors. Microbial dysbiosis and gut-brain axis disturbances are emerging as modifiable risk factors.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Neurodegeneration arises from complex interactions between genetic predispositions, protein misfolding, and immune dysregulation. Key mechanisms include: (1) prion-like propagation of misfolded proteins, (2) impaired autophagy and proteasome function, (3) neuroinflammation via microglial activation, and (4) synaptic dysfunction.
3.1 Microglial Activation¶
Microglia mediate neuroinflammation through cytokine release (IL-1 α , TNF) and phagocytosis of debris. Dysregulated activation contributes to neurotoxicity in AD, PD, and MS.
3.2 Astrocytic Dysfunction¶
Astrocytes regulate synaptic homeostasis and clearance of protein aggregates. Impaired astrocytic function leads to neuroinflammation and neurodegeneration in diseases like AD and ALS.
4. CLINICAL FEATURES¶
Clinical manifestations vary by disease but often include cognitive decline, motor dysfunction, and neuroinflammatory symptoms. Neurodegenerative diseases progress over years, while acute neuroinflammatory conditions (e.g., MS) may present with relapsing-remitting episodes.
4.1 Neurodegenerative Syndromes¶
Alzheimer's: Memory loss, amyloid plaques, and neurofibrillary tangles. Parkinson's: Tremors, bradykinesia, and Lewy bodies. Huntington's: Chorea, cognitive decline, and psychiatric symptoms.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnosis includes infectious encephalitis, autoimmune disorders (e.g., NMO), and psychiatric conditions. Biomarkers like CSF A β 42, tau, and neurofilament light chain help distinguish neurodegenerative from inflammatory diseases.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic tools include MRI for structural abnormalities, CSF analysis for biomarkers (e.g., A β , tau), and PET for amyloid imaging. Genetic testing identifies mutations in familial disorders (e.g., C9orf72 for ALS/FTD).
6.1 Biomarkers¶
CSF biomarkers (A β 42, total tau, phospho-tau) and plasma neurofilament light chain (NfL) are used to diagnose and monitor neurodegenerative diseases.
7. MANAGEMENT & TREATMENT¶
Therapies target neuroinflammation, protein clearance, and synaptic support. Monoclonal antibodies (e.g., aducanumab for AD), anti-inflammatory agents, and stem cell therapies are under investigation. Symptomatic management includes cholinesterase inhibitors and dopamine replacement.
7.1 Targeted Therapies¶
Anti-complement agents (e.g., eculizumab), TREM2 agonists, and autophagy enhancers (e.g., rapamycin) are experimental treatments. Gene therapy and stem cell transplantation are emerging approaches.
8. PROGNOSIS & COMPLICATIONS¶
Most neurodegenerative diseases are progressive and fatal. Complications include infections, falls, and psychiatric comorbidities. Early intervention may slow disease progression but not halt it.
9. SPECIAL CONSIDERATIONS¶
Pregnancy, pediatric, and geriatric considerations include drug safety, neurodevelopmental risks, and age-related comorbidities. Neuroimmunomodulation in pregnancy and stem cell therapies for pediatric neurodegenerations require careful risk-benefit analysis.
10. KEY POINTS & CLINICAL PEARLS¶
- Microglia and astrocytes are central to neuroinflammation and neurodegeneration. 2. Prion-like propagation of misfolded proteins drives many neurodegenerative diseases. 3. Stem cell-derived organoids enable patient-specific disease modeling and drug screening. 4. Targeting complement pathways and autophagy represents promising therapeutic strategies. 5. The gut-brain axis and microbiome influence neuroinflammatory and neurodegenerative processes.